Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.

Eli Lilly’s Q2 2026 revenue rose 48% YoY to about $23.0B, driven by Mounjaro (~$9.9B sales) and Zepbound (~$4.9B), reinforcing obesity as a multi-year growth engine. The article highlights Kisunla’s full FDA approval for early symptomatic Alzheimer’s and expanded international authorization, positioning Lilly with two large growth platforms (obesity/metabolic and Alzheimer’s). While management and pipeline breadth are portrayed as compelling, the stock’s run from <$700 to ~$1,240 over the past year and premium valuation versus peers temper the call for a “long-term buy.”

Analysis

LLY is evolving from a single-product growth story into a platform company with multiple shots on goal, but the market is already paying for that optionality. The key mechanism is not just end-market demand; it is whether manufacturing, payer access, and physician habit can sustain share gains faster than competitors can close the convenience gap. That keeps the relative winner/loser setup favorable to LLY versus NVO over the next 12 months, while making smaller obesity names dependent on data surprises rather than fundamentals.

The near-term risk is multiple compression, not a fundamental collapse. If next few quarters show any deceleration in prescription growth, gross margin drag from capacity buildout, or slower-than-expected adoption of oral/next-gen assets, a premium multiple can de-rate fast because the stock is now priced like a secular compounder, not a classic pharma. On the flip side, the Alzheimer’s angle is a longer-dated call option: meaningful for sentiment and pipeline credibility, but unlikely to move the P&L materially within 1-3 quarters unless uptake or reimbursement inflects sharply.

Consensus may be underestimating how fragile the “obvious winner” trade becomes once the category shifts from shortage-driven scarcity to competitive normalization. The more interesting trade is to own the durability of metabolic demand while fading the idea that every positive headline deserves a higher multiple. For 6-18 months, the falsifier is simple: evidence that LLY’s growth rate normalizes faster than expected while NVO or another competitor closes the convenience/supply gap.

Key Decisions for Investors

• Do not chase LLY after momentum spikes; prefer entry on 8-12% pullbacks or after any quarter where forward guide remains intact but the stock sells off on valuation.
• Relative-value: long LLY / short NVO for 3-6 months if you want exposure to obesity leadership while expressing that LLY’s execution runway is better than the market’s current skepticism implies.
• If you need lower-beta expression, buy a call spread on LLY 6-9 months out rather than stock; the payoff is tied to continued category leadership without full multiple risk.
• Watch for a reversal signal: any two-quarter slowdown in obesity script growth or margin compression from manufacturing expansion should trigger de-risking of long LLY positions.
• Avoid overallocating to smaller obesity pipeline names until oral data or payer adoption proves differentiation; the category is likely to consolidate around scale winners, not pure data optionality.